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INTRODUCTION 
 
      Epiphora  due to primary nasolacrimal duct obstruction is  an often encountered disorder 
in our community.The gold standard of treatment for Primary Acquired Nasolacrimal Duct 
Obstruction (PANDO) still remains the external approach of Dacryocystorhinostomy (EXT-
DCR)  technique ever  since its evolution in the early 20
th
 century. 
      The success rates achieved by Depuy-Dutemps and Bourguet (1) with this current 
technique reached 94% in the 1920s.Attempts were on to improve on this success rate with 
modifications but surprisingly it has stood the test of time with hardly much changes. 
But with the advent of better needles, fine suture materials , endoscopes, lasers, powered 
drills and modern anaesthetic techniques, the attempts were on again in the 1980s to further 
improve the success rates of DCR.More importantly, better endoscopic techniques has 
brought to focus the major causes for failure of external surgery,namely scarring within the 
anastomosis and at the common canaliculus, closure of the ostium by granulation 
tissue,ahesions to the medial wall of nose,and new bone formation. 
       Naturally, wound healing modulation with antifibrotic agents like Mitomycin C and 5 
Fluorouracil were the next logical adjuvants to DCR aimed at preventing proliferation of 
fibroblasts and thereby scar formation which could further potentially refine the success of 
DCR. 
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         Mitomycin C (MMC), is an alkylating agent which is used as an anti cancer drug and its 
is an antibiotic derived from Streptomyces caespitosus .It has a property to reduce collagen 
synthesis of fibroblasts by inhibiting DNA dependent RNA synthesis.It was being effectively 
used to improve outcomes of Trabeculectomy surgeries since the 1980s.Various studies 
which followed, used Mitomycin C in various concentrations and exposure durations as an 
adjuvant in both External and Endonasal DCR. 
      As of now, only limited number of trials has used intraoperative Mitomycin C in Ext-
DCR and of them very few are randomized controlled trials. Few studies suggested that there 
is a  significant difference in the success rates with MMC but the majority  of the other 
studies could not prove statistically significant increase in success of outcomes .Thus the 
results are equivocal. Of all the previous published studies, only 3 studies are done on Indian 
population. Also there is no standardisation of the use of MMC among researchers as to the 
concentration, technique and duration of exposure. 
       From the published data on the use of MMC, it seems that there could be a favourable 
and positive short-term effect of MMC, but there is not enough evidence regarding its long-
term effect of prevention of scarring at the rhinostomy site leading to failure of Ext DCR.But 
MMC cannot be used indiscriminately for all primary DCRs as it has very serious side effects 
and the risks-benefits has to be weighed carefully before inducting it in regular standard 
practice. Therefore, there is a definite need for more randomised control trials to come out 
with definitive results regarding its efficacy, duration and technique of application and 
adverse effects.  
         The proposed study would thus contribute to the literature on use of MMC in cases of 
Ext-DCR and the data thus obtained would help formulate protocols in the practice of the 
same in terms of the indication, duration and technique of application of MMC. 
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AIMS AND OBJECTIVES 
 
 
The aim of this study is to compare the success rates of External Dacryocystorhinostomy (Ext-DCR) 
with and without the intraoperative application of Mitomycin C (MMC) at the ostium site. 
 
 
 
 
 
 
 
 
 
 
4 
 
 
 
 
LITERATURE REVIEW 
 
         Epiphora or overflow of tears is a common complaint that is encountered in our day to 
day practise. It can be caused by anterior segment causes like a decrease in tear drainage or 
an increase in lacrimation,lid malpositions, eyelid margin disorders, tear instability or 
deficiency, trichiasis, superficial foreign bodies and cranial nerve V irritation.All these 
conditions cause an abnormal increase in tear production. When these conditions are ruled 
out, tear drainage abnormality is the likely diagnosis. 
        Abnormalities of tear drainage may be divided again into Functional and Anatomical. 
Functional failure can be caused by poor lacrimal pump function, which inturn may be 
caused by eyelid laxity, weak orbicularis, displaced punctum, or cranial nerve VII palsy. 
Anatomical obstruction can occur at any point along the lacrimal clearance pathway and can 
be Congenital or Acquired. 
Primary Acquired Nasolacrimal Duct Obstruction (PANDO) 
       The 2 categories of Acquired nasolacrimal drainage obstructions are Primary and 
Secondary. It was Linberg and McCormick introduced the term Primary Acquired 
Nasolacrimal Duct Obstruction (PANDO) in 1986.They described this entity as  nasolacrimal 
duct obstruction caused by inflammation or fibrosis without any precipitating cause (2). 
These studies have revealed oedema, vascular congestion, and inflammation of the 
nasolacrimal duct in the early phases.These changes ultimately resulted in fibrosis with 
complete occlusion of the nasolacrimal duct's lumen in the late phases.Later,Bartley proposed 
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an etiologic classification system for secondary acquired lacrimal drainage obstruction 
(SALDO) (3)(4). 
Epidemiology 
      Ancient Egyptians described symptoms attributable to lacrimal outflow obstruction in 
their papyrus writings according to the famous ophthalmic historian Julius Hirschberg. The 
Talmud of the Jews mentions lacrimal sac abnormalities. The term ‘epiphora’  can be traced 
back to ancient Greece and is based on the Greek word ‘epifora’. The  works of Hippocrates 
also mentions the relationship between aging and epiphora (5). 
       Despite the long historical recognition of the symptoms of lacrimal flow block as 
described above, there is only very little data available regarding the epidemiology of 
acquired lacrimal drainage obstruction. 
       Few have reported the incidence of this problem although symptomatic acquired 
nasolacrimal duct obstruction is so commonly encountered in clinical practice. Dalgleish 
reported a series of 3487 patients undergoing lacrimal irrigation before all intraocular 
procedures at one eye hospital in Manchestor,Great Briton.(6).He mentions the incidence of 
lacrimal obstruction to be 11%, increasing with patient age to over 30%. 
      An incidence of 20.24 per 100,000 has been reported in a study done in Olmsted County, 
Minnesota,USA (7). 
       The incidence of PANDO in the Indian subcontinent has not been quantified yet though 
it is a fairly common occurrence. 
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Gender variations 
          Traquair(8) stated that the males to females ratio attending ophthalmic outpatient 
clinics  with dacrocystitis is about 1:5. Duke Elder claims that this ratio can be extrapolated 
and that it applies to the incidence of dacryocystitis in the whole population  (9) . Stallard 
(1958) mentions that lacrimal duct obstruction is four times more commonly seen in females 
compared to males. It has been hypothesised that the smaller diameter of the lacrimal canal 
and the inferior bony lacrimal fossa in females may contribute to the increased occurence of 
nasolacrimal duct obstruction in females.(9) The loss of mucosal vascular plexuses in 
postmenopausal women is also thought to be a contributing factor. 
 
        Groessl et al (10) did research of this by serial axial CT scans on the bony lacrimal 
passage.They found that the in females, the bony nasolacrimal canal was narrower and flatter 
against the nasal floor compared to males. They also found that with increasing age up to 40 
years, the diameter and the sectional angle between the bony canal and the nasal floor also 
proportionately increased. 
 
     Janssen et al (11) also did axial CT scans  of the drainage passage measuring  the 
minimum diameter of the nasolacrimal duct.He found that compared to men,women had 
statistically smaller measurements. 
 
 However, it is observed that gender difference is not associated with difference in success 
rates of DCRs. 
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Age 
 
         It is observed that the incidence of PANDO increases with age. It is more common in 
adults over middle life from 5th to 7th decade(12)(13). 
 
Racial Variations 
 
      The nasolacrimal passage of Blacks and Asians is said to be wider and shorter compared 
to the Whites.This observation would lend credence to the finding that nasolacrimal 
obstruction occurs more often in Whites than other races (4). But more controlled comparison 
studies are needed to further augment this finding. 
External Dacryocystorhinostomy (EX-DCR) 
    The Gold standard for treatment for Primary Acquired Nasolacrimal Duct Obstruction is 
still External DCR. 
     A normally functioning lacrimal pump, properly positioned and patent puncta as well as a 
present and patent canaliculi are required for the operation to be successful. The preoperative 
assessment is aimed at confirming the presence of the above factors as well as at ruling out 
other potential causes of chronic epiphora. 
The aim of the surgery is to:- 
  Form a low-resistance tear drainage bypass between the conjunctival cul de sac and the 
nasal cavity, by converting the lacrimal sac into part of the lateral nasal wall. 
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Principles of Surgery are:- 
 1.Creation of an ostium in the lateral wall of nose adjacent to the sac.  
 2.Fashioning of the lacrimal sac flap and nasal mucosal flap 
 3.End to end anastomosis of flaps 
History of DCR 
       Surgical treatment of dacryocystitis stretches back nearly 2000 years. The first mention 
of lacrimal surgery appears to have happened  in about 1750 BC.It is mentioned  in the oldest 
recorded set of laws, the King of Babylon's Code of Hammurabi.(14) Celsus, in the first 
century, described a method of creating an artificial passageway into the nose by using hot 
cautery to puncture through the lacrimal bone(15). Several methods had been tried by 
surgeons in the early part of the 20th century. An interesting approach involved attempts to 
drain the lacrimal sac into the maxillary sinus. Intranasal approach operations had also been 
described(1). 
       In England, Woolhouse described the earliest operation that would resemble a modern 
external DCR in the 18th century. He advocated extirpating the sac, perforating the lacrimal 
bone and placing a drain made of silver, lead or gold (15). 
       Caldwell in 1893 and Toti in 1904 published what is considered the first modern 
description of external DCR(15). An external incision was made; the periosteum and the sac 
were elevated. A bony ostium was created using a punch. The medial sac wall was excised 
with the help of a canalicular probe as a guide. A corresponding piece of nasal mucosa was 
removed. The technique of suturing instead of excising of the  lacrimal sac and nasal mucosal 
flaps was described as early as 1914.  
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         Ohm in Germany and Depuy-Dutemps and Bourguet in France independently published 
what became the basis of truly modern DCR in the 1920’s(1). These surgeons popularised 
suturing of both the posterior and anterior flaps.        
         Depuy-Dutemps and Bourguet reported success rates of around 94%. Dupuy-Dutemps 
published the first major series of more than 1000 cases reporting a success rate greater than 
90% and set a standard that has been upheld in almost all study series emerging since then. 
Over the past decades, this procedure has undergone surprisingly few modifications. The 
arrival of better needles, fine suture materials, drills and modern anaesthetic techniques has 
however bettered the success outcomes of DCR. 
         Several modifications were developed throughout the 20th century in view of  the fears 
of significant bleeding when the angular vessels were encountered and  difficulties  in 
suturing both posterior and anterior flaps  (16). Issues such as incision placement, elevation 
of medial canthal tendon, , placement of stenting material, flap sutures, use of chisels, 
rongeurs, bone trephines, burrs  or cautery of posterior flaps and whether to suture the 
posterior flaps were explored and debated (17). 
Endoscopic DCR 
        In 1893 Caldwell first introduced the endonasal approach for lacrimal sac surgery. West 
in 1914 modified the technique(18). He introduced the concept of a window osteotomy to 
access the nasolacrimal sac and duct by removal of the lacrimal bone and the superior 
maxilla. Mainly due to the difficulties in visualising the intranasal anatomy these approaches 
did not gain present popularity. 
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          In 1989 the first clinical study of endoscopic DCR came to be published by 
McDonough and Meiring(19). With the introduction of better operating microscopes, 
fiberoptic delivery systems ,semirigid and rigid nasal endoscopes, the intranasal anatomy 
could be better visualised by the surgeons. 
        With the advent of Functional Endoscopic Sinus Surgery,semi-rigid and rigid 
endoscopes were used with increased frequency, particularly by otolaryngologists. In the era 
before the advent of   these advances, the popularity of the endonasal technique was limited 
by the bleeding from the nasal mucosa and poor visualization due to low illumination in the 
superior nasal cavity. As of now, the procedure is gaining popularity compared to 
conventional external dacryocystorhinostomy. 
  
        External and endoscopic dacryocystorhinostomy have the same goal ie to bypass of the 
blocked nasolacrimal duct by creating a passage above it so that the internal common 
canaliculus communicates directly with the nasal cavity through the lateral wall of nose. 
         The technique of surgery includes removal of the nasal mucosa overlying the lacrimal 
fossa.Additionally, the sac can be demonstrated by inserting a light pipe through the 
canaliculus. A rhinostomy is made using a rongeur or cutting burr to expose the medial and 
anterior walls of the sac.Then, the medial sac wall is excised. There is no formal anastomosis 
of nasal mucosal flap and lacrimal sac flap. Postoperatively.irrigation and removal of crusts 
and clots from the nose is done at frequent intervals. 
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Adjuvants to Endonasal DCR 
 
Laser assisted Endo-DCR 
 
        In 1982  came an  important observation by Linberg  (20)  that the final healed ostium 
shrinked to only 2% the size of the initial peroperative ostium and that it  was enough to 
provide good functional results.Taking note of this, more and more surgeons increasingly  
used  endoscopic approach  in lacrimal  surgery and explored the use of lasers in DCR. 
 
        Gonnering et al (21) came forward with the first clinical study of endonasal laser-
assisted DCR, which used the carbon dioxide (CO2) and potassium titanyl phosphate 
(KTP)/neodynium-yttrium-garnet (YAG) laser for osteotomy. 
 
        Woog et al (22) studied  the use of the holmium:YAG laser for bone removal. He said 
that the holmium:YAG satisfactorily  fulfilled the  characteristics of  an ideal laser for 
endolaser DCR namely the  ability to be delivered through a flexible fiberoptic delivery 
system, excellent haemostasis ,efficient bone ablation and minimal collateral damage. The 
overall long-term ostium patency rate in their series was 82%. 
 
        The laser of different wavelengths used to perform osteotomy as part of the DCR 
,mostly transnasal approach are Holmium:Yttrium-Aluminum-Garnet (Ho:YAG) laser, 
potassium-titanyl-phosphate (KTP) laser, Erbium:YAG (Er:YAG) laser, Neodymium:YAG 
(Nd:YAG) laser and diode laser (23). 
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        With success rates of the  laser assisted technique ranging from 64% to 85% ,this 
technique seems to be less effective than cold steel endoscopic DCR (24). The reasons for 
these inferior results could be due to the small size of the osteotomy. Most lasers can only 
create a 5–8 mm osteotomy because they only remove the thin lacrimal bone at the postero 
inferior aspect of the lacrimal sac .The DCRs with small ostia created by laser were found to 
have patency rates of only 70%. . But if an attempt is made to remove the rest of the thick 
bone with a laser, then the excessive heat generated may increase tissue damage and 
postoperative fibrosis, scarring and stenosis. 
 
         Umapathi et al (25) reported long term results for Laser assisted DCRs .He had a 5 year 
follow up  data showing poor long term results declining to even 56%. 
 
Radiofrequency assisted Endo DCR 
 
        Javate et al (26) introduced a radiofrequency unit for incision of the nasal mucosa and 
bone during Endo-DCR which simultaneously coagulates and cuts with minimal thermal  
collateral damage. The study attained a 90% success rate at 3 months follow up. 
 
 
Powered Cold Steel Endo DCR 
 
         The challenge in Endo-DCR is the full exposure of the sac.The hard bone of the frontal 
process covers the upper half of the sac. Maximum exposure of the sac requires maximal 
removal of an extensive area of the thick bone above the axilla of the middle turbinate and 
the lateral wall of the agger nasi cell.  
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         This cannot be achieved without using a chisel or powered drill. The results of Endo 
DCR can be bettered by a full lacrimal sac exposure and larger rhinostomy as it is thought 
that the larger size of the ostium, better the outcome of DCR surgery. This could be best 
achieved with a diamond burr drill as it allows easy and rapid bone removal while protecting 
the sac mucosa from damage. 
 
       An angled (15°) coarse diamond burr attached to a microdebrider is used to for this 
purpose.. At the end of the surgery, the U-shaped flap fashioned facilitates primary intention 
healing along the posterior, inferior and superior edges of the junction between the sac and 
nasal wall. The anterior edge of the rhinostomy remains uncovered by mucosa which gets 
healed by secondary intention. 
 
        Wormald et al (27) in his series published a high success rate of 95% at 11 months post 
operative assessment with  this method which was comparable to that of External DCR. 
 
 
Trans Canalicular DCR 
 
        A 600-micron fibreoptic with a blunt hemispherical tip of neodymium:YAG (Nd:YAG) 
laser  is inserted via the  punctum. With intranasal endoscopic control, a rhinostomy is 
created with the laser. Ducts are intubated with Silicon tubes left in place for 6 months. 
 
        Pearlman et al (28) did 49 such procedures  with a success rate of 85% . This surgical 
technique affords a simple, incisionless, bloodless alternative to conventional DCR. 
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          Eloy et al (29) in 2000, first reported the  use of a diode laser for canalicular DCR  with 
success rate of 58%. Fernandez et al (30) in 2004 reported a success rate of 90 %.But 
generally success rates are lower probably because of the small initial ostium created as 
compared with External DCR. One study by Pal et al (23) showed a final ostium size of 
average 5mm at 6 month follow up giving him a success rate of 69%. 
 
Advantages of External DCR over Endonasal DCR 
 Good exposure of the whole Sac 
 Primary intention healing of mucosal flaps promoted by sutured apposition 
 Preparation of a large ostium  
 Allows ready access for the surgical management of canalicular disease; this includes 
canaliculo-DCR, open placement of a canalicular bypass tube or retrograde 
canaliculostomy and intubation. 
 Provides direct visualization of abnormalities of the lacrimal sac – including stones, 
tumors or foreign bodies   
 Cost effective 
 Shorter operating time  
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Advantages of Endonasal DCR over External DCR 
• Avoidance of a facial scar;Better cosmesis 
• Preservation of the lacrimal pump mechanism.The absence of an external   incision 
decreses the risk of damage to the orbicularis oculi muscle, medial canthal ligament 
and pretarsal fibres which are essential for an intact lacrimal pump. 
• Earlier postoperative recovery time 
• Simultaneous correction of the intranasal causes contributing to the NLD obstruction 
• Lower rates of  regurgitation of air while blowing nose (31)  
• Lower risk of CSF rhinorrhea 
• In good hands success rates match that of external DCR.  
 
Success rates of External DCR 
         Leong et al (32) did a systematic review of the literature  from January 1966 to 
December 2008 for the clinical outcomes of DCRs. A total of 73 studies that fulfilled the 
inclusion criteria were analyzed. A total of 4800 patients were pooled, from which 4921 
DCRs were performed. Success varied between 65 and 100% after External DCR compared 
with Endonasal DCR, which varied from 84 to 94%. The success rate of Laser assisted 
Endonasal DCR varied widely between 47 and 100%. The wide range of success rates may 
be related to patient demographics, surgical variability, and dearth of standardised outcome 
measures. 
        Also the success rates are found to drop with passing time .In a study done by Mansour 
et al (33) in Netherlands on 139 External DCRs, the success rate was 89% after 1 year, 
reducing to 79% after 2–3 years and  further to 71% after 4–5 years. 
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      Even with the advent of above mentioned minimally invasive DCR techniques and their 
advantages,the external approach still remains the gold standard against  which other methods 
are compared. 
Functional Vs Anatomical success rate- “The Lacrimal paradox” 
           Patient satisfaction, quantified by the subjective and functional success is of prime 
importance as DCR is mostly performed to improve the quality of life of the patient. The 
patency of lacrimal passage is secondary. 
         The functional success rate is found to be less than the anatomical success rates in many 
studies.Fayers et al (34) studied outcomes  for 124 external DCRs  which showed an overall 
anatomical success of 74% but a functional success of  only 69% . 
          Geoff Rose (35) tries to  describe this as the “lacrimal paradox”.This means that  
anatomical patency rates may not correlate with subjective  success  and vice versa. He 
explains that the symptoms of drainage disorders are either Volume related or Flow related. 
In most cases Volume related backwash from the lacrimal sac can be treated with lacrimal 
surgery.But  the Flow-related epiphoras are largely due to limitations in  tear conductance 
from the lateral canthus to the nasal cavity. Patient satisfaction of flow-related symptoms may 
not achievable in every case, and especially when there is hydraulic resistance in both the 
canaliculi and the duct. 
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Analysis of Causes of Failure in DCR 
Factors noted to be the reasons for failure are 
 Fibrous tissue growth 
 Inappropriate size / location of bony ostium 
 Sump syndrome 
 Collapse of the bridge between anterior flaps 
 Adhesion of the anterior to the posterior flaps 
 Obstruction of the bony window with new bone formation 
 Untreated common canalicular obstruction 
 Intranasal adhesions 
 Septate sacs incompletely connected to the nose 
 
 
Role of Ostium size 
 
          The general teaching is that a large bony resection of 15–20 mm in external DCR is 
required to ensure a large anastomosis and thus a high success rate. With the use of intranasal 
endoscopes it has been possible to assess the characteristics of the healed intranasal ostium in 
external DCR. 
 
        Lindberg et al (20) did a landmark study of  a series of 22 external DCRs. There was no  
correlation of statistical significance between the size of the intra operative ostium size and 
the final intranasal ostium.  
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          He  found that the average diameter of the healed ostium was 1.8 mm, inspite of an 
initial diameter averaging 11.8 mm intraoperatively.Other authors have consistently used his 
findings  to support the argument that large osteotomies does not play a role in the final 
success.But on the contrary, this result could  also suggest that  if the large rhinostomies 
made  in external DCR shrink to such an extent on healing, then it could be  likely that 
smaller osteotomies produced endonasally could  narrow to an extent where there could be a 
failure in adequate tear drainage. 
          Another argument is that in a well done external DCR, the lacrimal sac eventually  
becomes incorporated into the lateral wall of the nose and it could well be doubted if  
the endonasal measurements show the opening of the common canaliculus rather than the 
ostium. 
         The most important observation was that excellent functional success resulted  even 
when the final  ostium was quite small (20). 
          Performing a large osteotomy is one of the recommendations to increase the success 
rate of DCR. However, there is no agreement on the dimensions of the rhinostomy to be 
created. 
 
         Welham and Wulc (36) observed that 111 out of 208 cases of external DCR,  a revision 
surgery  was necessary due to  inappropriate location or size  of the bony opening. 
Thus the size of the bony ostium is considered as an important factor for a successful surgery 
(37). 
 
     Iliff  made  only a 10 mm diameter bony ostium, and he reported  a success rate of more 
than 90%. In his failure cases, reunion of the bony opening was noted (13). 
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         Even when the two main factors for success namely bony ostium of an appropriate 
location and size,combined with a technically perfect anastomosis, are expected to give a 
100%  long term success, it is not the reality.This could be due to the probability that the  
osteotomy  created is not standard-sized, and when it is found that the bony ostium size is 
adequate to do the anastomosis, additional bone is not removed. Thus the bony ostium  may 
not be of a size critical for adequate drainage. 
 
          Argin et al (38) even proposed to have a critical ostium size of  20 x 20 mm  with his 
patients having 100% anatomical patency at a mean follow up of 31 months. The upper 
margin of the ostium extended to around 5mm superior to the internal opening of the 
common canalicus, and the lower margin included the bony nasolacrimal, measuring 2 cm in 
the vertical axis. In horizontal axis, the posterior bony margin was a precisely preserved 
posterior lacrimal crest, and an anterior ethmoidectomy was  performed giving a 2 cm 
defect.No cases of CSF rhinorrhoea were reported by them.  
 
          With the larger osteotomy sizes, the question of the safety of the procedure arises as to 
the chances of cerebrospinal fluid leakage. Botek (39) in his cadaver study, found that the  
margin of safety between internal common canaliculus opening and the anterior part of the 
cribriform plate was approximately 25 mm. 
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Location of Ostium 
 
       A low location of  ostium may not bypass an upper or mid sac obstruction; likewise an 
ostium located in a high position leaves the  remnant nasolacrimal duct acting as a blind 
pouch vulnerable to reinfection and Sump syndrome. 
 
New bone formation 
 
        As a general principle new bone formation requires the presence of periosteum and, in 
patients undergoing dacryocystorhinostomy, the periosteum is stripped away, thereby  
possibly minimising the chances of  new bone formation. Primary epithelial closure almost 
certainly inhibits the new bone formation otherwise likely to occur with secondary intention 
healing(40). 
       Some authors have reported that bone regrowth is occasionally causative for failure of 
primary surgery (41). 
        Others maintain that bony regrowth do not occur and that fibrous  scar tissue  is 
primarily causative for obstructions at the anastomosis site (42). 
 
Role of Scarring  
 
     Tissues must be repaired whenever possible by primary rather than secondary intention 
which is a basic surgical principle. An unopposed mucosal flap can result in secondary 
haemorrhage, infection and excessive granulation and scarring. This might result in the 
inadequate passage of tears through a scar rather than through an ideal mucosa lined orifice. 
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         Ever since the first descriptions of DCR operations, authors reporting  many large series 
have brought modifications to  the technique and have reviewed the causes of failure in those 
whom DCR resulted  in no relief of epiphora. On revision surgery of these cases, scarring 
within the anastomosis site was commonly noted in all these series(41)(43)(44). 
 
         In the series of Welham et al (36) with 128 patients, the scarring noted was divided into 
two locations.First, a localised common canalicular scar, probably due to persistent sac 
disease following the first surgery was found in 111 cases. Second, a dense scarring within 
the anastomosis was found in 17 cases. 
 
Advantages of Single anterior flaps Vs Double flap technique 
           Jones (45) and Welham(46) pointed out that even though the suturing of the anterior 
and posterior  flaps increases the chances of primary intention healing of the mucosal 
anastomosis,the single flap technique is simpler to perform in lacrimal surgery. Double flap 
suturing also helps with the control of intra-operative primary and secondary bleeding and 
fibrosis later on. Posterior flaps are technically difficult to anastomose. In the posterior part of 
the rhinostomy site, because of the close proximity of the sac and nasal mucosal flaps, it is 
likely that they would scar together. 
 
 
           Welham says that accurate  anastomosis of mucosal flaps can incresase the  success 
rates for external DCR  to well above 90% (46). 
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            In a study by Yazici et al (47), they compared 2 groups randomized by anastomosis 
techniques of single anterior and double flaps.The single flap group showed larger mean 
ostium height  than in those with double flap anastomosis.But this difference was not 
statistically significant.The results of this study correlates  with the  observation that the 
intranasal ostium heals to a much smaller size, irrespective of whether only one anterior flap 
or both the anterior and posterior flaps were fashioned (21). 
 
         The anterior flap technique without posterior flaps has many advantages as well. There 
is less obstruction of the secretions by posterior flaps .Supposedly there are fewer  internal 
openings in the drainage cavity, thus  less chance of obstruction due to scarring  around the 
common internal punctum. With posterior flaps there is an increased chance of sump 
syndrome where as there are lesser chances of infection with only anterior flaps. Finally, with 
anterior flap alone, the lacrimal sac remnant integrates well into the lateral nasal wall thus 
permitting tears  to drain directly  into the nose (48). 
         Becker (49) did a series of  external DCRs without any flaps and surprisingly reported a 
success rate of 90%. He made large osteotomies with precise excision of adjacent mucosa 
and thereby having no redundant mucosal tissue in the osteotomy site leaving only a small 
gap for the remaining edges of the nasal mucosa and sac to scar to each other across the 
rhinostomy. 
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DCR with Intubation using Stents 
       Use of stents in lacrimal surgery was welcomed as a major advance in this field.But  the 
debate is still going on regarding the role of silicone intubation in the surgical management of 
acquired nasolacrimal duct obstruction  not associated with canalicular pathology .Some 
lacrimal surgeons use intubation  routinely, wary of the ‘just in case’  postoperative scarring 
at the internal punctum of the common canaliculus,But we know  that success rates in these 
cases already do approach 100% without the use of silicon stenting. 
 
         A randomized clinical trial  in 100 patients by Choung et al (50) on the efficacy of  
external DCR with and without silicon intubation in uncomplicated primary nasolacrimal 
duct obstruction  showed that the six-month subjective and anatomic success rate was 90% in 
intubation group and 87% in the non intubation group. But the better result in stent patients 
was not statistically significant. 
 
        In a prospective randomised study of primary Endonasal DCRs with and without silicon 
tube intubation by Smirnov et al (51) ,the results showed success rate at 6 months with 
silicone tube  as 78%, and without silicone tube as 100% the difference being statistically 
significant. They advised not to use stent for primary surgeries. 
 
         Thus according to current evidence, silicone intubation is not associated with better 
functional and anatomical success rates in DCRs for patients with uncomplicated primary 
nasolacrimal duct obstruction without common canalicular disease (52). 
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        Allen et al (53) observed that silicone stenting of the nasolacrimal duct was associated 
with an increase in the failure rate of primary DCR which showed statistical significance. 
They postulated that silicone tube by inciting granuloma formation in the drainage cavity, 
predisposed to DCR failure. 
          Thus, routine use of silicone intubation in DCR should be avoided except for cases like 
canalicular stenosis, small contracted or scarred lacrimal sac,a large valve of Rosenmueller 
occluding the common canaliculus or for revision DCR. 
           Its complications and side effects include corneal irritation, lacrimal sac mucosal 
granuloma formation, slitting of the punctae and canaliculi,tube displacement and difficulty 
in tube removal. 
       Based on a  meta-analysis (54) that included 5 randomized controlled trials and 4 cohort 
studies analysing 514 cases of external DCR , endonasal laser-assisted , and nonlaser 
endoscopic endonasal DCR techniques with and without silicon intubation,.no benefit was 
found for silicone tube intubation in primary DCR. 
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Wound Modulation in DCR 
       Two common causes of failure in DCR  are closure of the osteotomy site  and common 
canaliculus by fibrous scar tissue (44) .Thus it has been suggested that modulation of the 
wound healing in the anastomosis cavity may improve the outcome of DCR by  preventing  
 excessive fibroblast proliferation and scarring.  
 
       Fibroblasts are the central cells in the scarring mechanism. The most important steps in 
wound healing are the proliferation, migration, and extracellular matrix production by these 
cells. 
         Antifibrotis like Mitomycin C (MMC) and 5-Fluorouracil, were first used for 
modulation of  the wound healing proccess in the early 1980s. Mitomycin C's alkylating 
properties inhibit DNA replication, which led to its use first as an anti-cancer drug. Most of 
the  studies on MMC's efficacy followed a clinical work done by Chen (55). 
 
What is Mytomycin C (MMC)? 
 
          Mitomycin C (MMC) is obtaned from the bacteria Streptomyces caespitosus.It acts as a 
bioreductive alkylating agent. Oxygen radicals are generated by a bioreduced MMC which 
alkylates DNA, and produces interstrand DNA cross-linking resulting in inhibition of DNA 
synthesis.It is preferentially toxic to hypoxic cells. MMC at high concentrations also inhibits 
RNA and protein synthesis. It inhibits fibroblast collagen synthesis by inhibition of DNA 
dependent RNA synthesis. 
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            It is used systemically as an anti cancer agent for the treatment of GIT 
malignancies,breast cancer, urinary bladder carcinoma, non-small cell lung cancer and many 
others. 
 
          Serious side effects in systemic use noted are haemolytic uremic syndrome, bone 
marrow suppression, hepatic and renal toxicity. Accidental skin exposure can cause 
ulceration and necrosis of the area or can erode vessels leading to haemorrhage. 
 
         Mitomycin-C should not routinely be administered to patients who are pregnant, who 
could be pregnant or to nursing mothers. Animal studies have shown teratological changes 
(56). 
 
Clinical Efficacy of Mitomycin C 
 
          The antifibrotic action of MMC has been now established and application in 
ophthalmology include glaucoma surgery, pterygium excision, refractive corneal surgery, 
conjunctival neoplasia and cicatricial eye disease (57)(58). 
 
            With the clinically used concentrations MMC inhibits or causes apoptosis of  the 
fibroblast cells involved in the scarring respone of  tenons capsule (59). 
 
           A 2005 Cochrane review (60) of the use of intraoperative MMC in Glaucoma filtration 
surgeries showed to reduce the risk of surgical failure rates in eyes at high risk for failure and  
primary trabeculectomies. There was no significant increase in other side effects with its use. 
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            Hu et al  (61) studied  the effect of MMC on cultured human nasal mucosa fibroblasts. 
The inhibition rates of 0.4 mg/ml MMC for 5-minute duration of exposure was 31%.  
           He concluded that short exposure to MMC causes cytotoxicity, inhibits proliferation 
and also increases apoptosis of fibroblasts. Fibroblast apoptosis decreases the amount of cells 
available for proliferation and decrease product secretion for scarring. He also suggested that 
his study was in vitro study and greater concentrations than 0.5 mg/ml could be required to 
have a clinical efficacy when used in DCR. 
          Yalaz et al  (62) evaluated the effects of antifibrotic agents on the fibrous tissue at the 
site of surgical rhinostomy in external DCR. 60 cases of PANDO were grouped to 3 groups 
of 20 each. MMC was applied to the first group (0.5 mg/ml to 10 and 1 mg/ml to 10 
cases).The second group received 5-flourouracil (2.5 mg/ml to 10 and 5 mg/ml to 10 cases). 
The control group was 20 cases. 
        A successful outcome in MMC and 5FU groups was reported as 95% and 90% 
respectively. The average follow-up time was 15 months. The tissues obtained during the 
revision of failure cases were evaluated by light and electron microscopy.Light microscopy 
of the tissues showed  hypo and acellular areas to be dominant in the antiproliferatives groups 
and an increased  fibroblastic activity among the controls.  
         Electron microscopy revealed fibroblasts with scanty cytoplasms poor in organelles and 
nuclear fragmentation, necrosis or pyknosis in the antifibrotics group. 
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Results of previous studies using MMC in External DCR 
 
     Qadir et al (63) studied 50 cases of PANDO and divided them to MMC group and Control 
group of 25 patients each. He used 0.2mg/ml MMC intraoperatively in  external DCR for 5 
minutes. Subjective symptoms, tear meniscus height and syringing of ducts were done to 
assess the results. The subjective and anatomical success rates were 96 % in MMC and 80% 
in control group respectively at 6 months follow up. There was no statistical difference 
between the outcomes between the two groups. 
 
     Satish et al (64) did a prospective randomised control trial on 60 patients with PANDO. 
They used 0.2mg/ml MMC intraoperatively for a duration of 5 minutes. Subjective 
symptoms, tear meniscus height and syringing of ducts were done to assess the results. They 
reported a statistically significant higher success rate of 96% in MMC group at 6 months 
follow up compared to 73% in the control group. They thus reported a slightly lower 
percentage of success in control group as compared to studies done earlier. 
 
     Deka et al (65) did a comparative study of 60 cases and divided them into 3 groups of 20 
each. Group 1 received no MMC while Group 2 and  3, MMC at a concentration of 0.05 
mg/mL and 0.4 mg/mL respectively was used  for 2 min.  A single-flap DCR  was performed 
for half of the cases in each group and  double-flap technique for other half.  
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     Endoscopic nasal evaluation was done at  day 1, 2 weeks and at 6 months post operatively. 
At the end of the final follow up, symptomatic relief had no significant difference among the 
three groups.  
     Size of the ostium was found to be more in group 3 (17.5mm
2
) compared to Group 2 
(4.8mm
2
) and Group 1 (3.6mm
2
) in the single flap group. No statistically significant 
difference was observed between the rhinostium size in single and double flap DCR.The 
overall success rate was 90 % in control group and 95% each in MMC groups, which was not 
statistically significant. 
 
 
     Kao et al(66) studied 15 eyes with PANDO and used 0.2mg/ml MMC for 30 minutes. 
Symptomatic success in the MMC group was 100%  and  that in controls was 87.5%. 2 
patients in the control group was found to have septo-osteotomy adhesion but for none in the 
MMC group. Although immediate postoperatively,the surface area of the ostium showed no 
significant difference among 2 groups, bigger ostium was noted at 6 months in MMC group 
which was statistically significant. 
 
     You et al (67) studied 50 cases and divided them into a control group and 2 MMC groups. 
Two MMC groups received 0.2 mg/ml MMC (group 1) or 0.5 mg/ml MMC (group 2) at 
osteotomy site for 5 minutes. At final follow up visit, ducts were patent in 83% of the control 
group, 100% in MMC group 1, and 94%  in MMC group 2. The average ostium size was 22.2 
mm
2
 in MMC group 1, 20.6 mm
2
 in MMC group 2, and 13.2 mm
2
 in controls. The difference 
in the mean ostium size between MMC and control arms was significant at 35 months follow 
up. But between the two MMC arms, no statistically significant difference was observed. 
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       Liao et al (68) studied 88 patients. In the MMC group, 0.2 mg/ml MMC was applied to 
the rhinostomy site for 30 minutes duration. The outcomes were objective findings such as 
irrigation and the height of tear meniscus and subjective improvement of watering.A 
statistically significant difference between groups at 10 months follow up was noted. 
Subjective success was 95.5% in MMC group while it was 70.5% in the control group at 10 
months follow up; 4.5% and 11.4% was the duct non-patency rate on syringing in MMC and 
control groups respectively. 
 
      Ari et al (69) did a prospective randomised control trial of  100 cases and intraoperative 
MMC 0.2 mg/mL was kept at  the rhinostomy site for 30 minutes in the MMC group. The 
outcome measures were objective findings, irrigation and the improvement in height of tear 
meniscus, and subjective symptoms.90% in the MMC group and 66% the control group were 
symptom free at 1-year follow up which was significant( P=0.005).The patency success rates 
were greater in the MMC group than the control group  96% vs 84%( P=0.005) which was 
also significant.  
 
     Yildrim et al (70) did a randomised control study of  40 eyes with 20  receiving 0.2mg/ml 
MMC for 30 mins .Follow up period was 1 year.18/20 (90%) eyes in the MMC group  had no 
watering and 1 patient  (5%) had an improvement. While in the control group, only 12/20 
(60%) eyes had no symptoms and  5 (25%) of the eyes had an improvement. Success rate was 
85% in controls and 95% in MMC group with regard to patency of ducts at 1 year follow up 
but difference did not reach statistical significance. 
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     Roozitalab et al (71) studied 130 patients and divided them into 2 groups.MMC group 
received  0.2mg/ml MMC for 30 mins.Outcome measures were subjective symptoms and the 
tear meniscus height, fluorescein dye disappearance test, and duct patency. Objective and 
subjective success rates in the MMC group was 90.5% (59/65), and in the conventional group 
was 92.4% (60/65) at 6 months follow up. The two groups showed no significant difference 
in outcomes.Thus it was concluded that in DCR, intraoperative MMC does not improve its 
success rate. 
 
     Gonzalvo et al (72)   studied  the effect of intraoperative MMC in external 
dacryocystorhinostomy (DCR),  and osteotomy size with helical computed tomography 
(HCT).He studied 17 patients. HCT scans were performed within 24 hours after operation 
and then at 1, 3 and 6 months to assess the osteotomy size. He used 0.2mg/ml MMC for 2 
mins.  
       100% patients remained asymptomatic in the MMC group and 75% in the controls. The 
percentage of the remaining osteotomy size in comparision with the  size immediately after 
surgery in  the MMC group at the end of 6 months was 93.8 %  whereas that of the control 
group was only 64.8 % (p<0,001). These statistically significant differences were noted at 1, 
3 and 6 months concluding that MMC is effective in reducing the shrinkage rate of the 
rhinostomy after DCR. 
 
     Rahman et al (73) studied 90 patients with PANDO and placed 0.2ml/mg MMC during 
external DCR for 10 minutes.There was no control group. At 6 months follow up,he reported 
a functional and  anatomical success rate of 97%. 
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     Feng et al (74) recently did a comprehensive meta analysis to assess the efficacy and 
safety of local application of intraoperative MMC at the osteotomy site in primary external 
dacryocystorhinostomy. Nine RCTs reporting on a total of 562 DCRs were included in the 
meta-analysis.  
       Results showed a significantly better success rate in the MMC group compared to the 
control group (p = 0. 01). In two RCTs, the mean osteotomy size 6 months postoperatively 
was significantly larger in the MMC group than in the control group. No intraoperative or 
postoperative complications except two cases with delayed healing of the external skin 
wound were recorded in the MMC group. Further prospective, randomized studies involving 
larger patient numbers were suggested. 
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Table1- Previous studies using MMC in EXT-DCR and their results 
 
Author Year Country Type Sample
size 
Success 
MMC 
% 
Success 
Control 
% 
Conc 
MMC 
mg/ml 
Duration 
MMC 
min 
F/U 
months 
Result 
           
Quadir 2013 India CC 50 96 80 0.2 5 6 - 
Satish 2013 India RCT 60 96 73 0.2 5 6 + 
Ari 2009 Turkey RCT 100 96 84 0.2 30 12 + 
Yildrim 2007 Turkey RCT 40 95 85 0.2 30 12 - 
Rahman 2006 Pak CS 90 97 - 0.2 10 6  
Deka 2006 India CC 60 95 90 0.4 2 6 - 
Roozitalab 2004 Iran CC 130 90 92 0.2 30 6 - 
You 2001 China CC 50 100 83 0.2 5 35 + 
Gonzalvo 2000 Spain CC 17 100 75 0.2 2 4 - 
Liao 2000 Taiwan CC 88 96 89 0.2 30 10 + 
Yalaz 1999 Turkey CC 60 100 90 1 - 15 - 
Kao 1997 China CC 15 100 87 0.2 30 6 - 
 
*Result  + means significant difference and – means no significant difference 
CC-comparative study;RCT-randomised control trial;CS-case series 
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Efficacy of MMC in Endonasal DCR (EN-DCR) 
 
      Numerous studies have come out regarding the use of Mitomycin C as an adjuvant in 
both Primary and Revision Endonasal DCR. 
       Some investigators like Qin et al (75) ,Ozkiriş et al (76) and Rekha Mudhol et al  (77) 
have reported  improvement in the success rate of Endo-DCR with the use of MMC, whereas 
others like Prassannaraj et al (78), Tirakunwichcha et al (79) and Farahanai et al(80) 
suggested that  intraoperative MMC in Endo-DCR  surgery did not improve the success rate 
of surgery. 
     Very recently, meta analysis and systematic review to evaluate the efficacy of 
intraoperative mitomycin C application in both Primary and Revision Endo-DCR surgery was 
done by Cheng et al (81).They did a systematic search on PubMed, Cochrane Central 
Register and Embase  from January 1990 to December 2012. 11 comparative studies (9 RCTs 
and 2 non-RCTs) were part of the meta-analysis and comprised a total of 574 eyes. 
       The average follow-up period was from 6 to 18.2 months. 0.2- 0.5 mg/ml MMC was 
applied at the rhinostomy site for 2 to 15 minutes. 
        The overall success rate was 90% in the MMC surgeries and 79% in the controls which 
was significant (p = 0.004) except in the subgroup of  silicone intubation Endo-DCR. The 
measured rhinostomy size  was significantly larger in the MMC group than the control group 
at 3 months ( p = 0.041) and 6 months (p = 0.008). But, this difference became negligible at 
12 months after surgery (p = 0.072). No complications were reported related to MMC use in 
any study. 
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Efficacy of MMC in Revision DCR 
 
     Yeatts et al (82) used 0.3mg/ml MMC to the fistula site of 8 cases of failed External DCR 
for 3 minutes.The mean follow-up period was 14.6 months. He reported an overall success 
rate of 100%.No postoperative complications associated with the use of Mitomycin C were 
observed. 
       In the Cheng et al (81) meta analysis, in the sub group of Revision  Endo DCR, four 
studies on 144 eyes were analysed. The studies included were Oskiris et al(76), Zilelioglu et 
al (83), Penttila et al (84) and Ragab et al (85).Of these, only Oskiris study showed a 
standalone significant difference between the two groups while other studies could not prove 
significance. But the overall meta analysis result showed that significantly higher (p = 0.029)   
success rate was in the MMC group. 
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PATIENTS AND METHODS 
 
Study Design 
This study is a randomized, parallel group, placebo controlled double blind trial. 
 
Study Population 
Our  study population was the patients attending the outpatient department of our hospital and 
also those attending the outreach camp clinics.The patients from Vellore and neighbouring 
districts of Chitoor,Kancheepuram and Thiruvannamalai were recruited after informed 
consent  and if found willing for a follow up as per the study guidelines. 
 
Setting 
The study was conducted from 25
th
 October 2012 till 31
st
 October 2013 in the Department of 
Ophthalmology,Christian Medical College,Vellore,TamilNadu,India.A feasibility study 
regarding the default technique to be followed and the duration,concentration and placement 
of MMC was done prior to submitting the proposal for IRB clearance. 
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Inclusion Criteria 
Participants who are of age 18 years and above with Primary Acquired Nasolacrimal Duct 
Obstruction (PANDO). 
 
Exclusion Criteria 
1.Secondary causes of Nasolacrimal duct obstruction 
 Trauma 
.Nasal pathologies like 
 Symptomatic Deviated Nasal Septum 
 Active Sinusitis 
 Nasal polyps  
 Nasal Tumors 
 Atrophic rhinitis 
2. Revision DCR 
3.  DCR with Stents 
4. Renal failure or Immunosuppression 
5. Pregnancy and lactation 
6.Past Radiation Therapy 
7.Past Chemotherapy 
8. Out station patients not able to come for follow up 
9. Patients who did not consent for the enrolment into the study 
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Pre Operative Evaluation 
 History 
 Relevant history of  patient’s main complaints 
 Past history suggestive of dacryocystitis and its management 
 Any ENT complaints 
 Any Co-morbidities like Diabetes mellitus,Hypertension, Keloid 
tendencies,Bleeding tendencies 
 Any antiplatelent or anticoagulation therapy 
 Past Ocular /Lacrimal/ENT surgeries. 
 Past Local Radiation therapy/Chemotherapy 
 
 Best Corrected Visual Acuity 
 Regurgitation on Pressure Over Lacrimal Sac (ROPLAS) 
 Complete Slit-lamp Anterior and Posterior Segment Examination 
 Munk’s score of Epiphora (86) 
 
                 Grade 0 -No epiphora 
 
                 Grade 1- Occasional epiphora requiring dabbing less than  twice a day 
 
                 Grade 2 -Epiphora requiring dabbing two to four times per day 
 
                 Grade 3- Epiphora requiring dabbing 5–10 times per day 
 
                 Grade 4- Epiphora requiring dabbing more than 10 times per day 
 
                 Grade 5- Constant tearing 
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 Fluorescein Dye Disappearance Test (FDDT) (87) 
         Fluorescein strip wetted by 1 drop of Hydroxypropyl Methyl cellulose 3% artificial 
tears  is touched on inferior conjunctival cul de sac.Both eyes are tested simultaneously.The 
patient is kept from wiping or dabbing tears.The dye disappearance test is graded at 5 minutes 
on a scale from 0 to 4+ ; 0 represents no dye remaining and 4+ indicates that virtually all of 
the dye remains. While 1+ or 0 represents minimal or no residual amount of the dye,a 
residual amount of  2+ to 4+ is considered an indication for inadequate lacrimal drainage. 
 Syringing of the Nasolacrimal Duct 
 
Technique of External Dacryocystorhinostomy 
Pre Operative  Evaluation 
Haemoglobin levels 
Blood sugar 
Blood Pressure 
Anterior Rhinoscopy – done with Thudicam speculum to rule out any intra nasal pathologies 
as listed in the exclusion criteria. 
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Pre operative Medication 
     Injection Fortwin 1ml+ Phenergan 1 ml is given intramuscularly half an hour prior to the 
start of surgery. 
Anaesthsia 
     Local anesthesia is given by both infiltration as well as topical application. For infiltration 
2% lignocaine with 0.5% Bupivacaine with or without adrenaline is used. Infratrochlear 
nerve that supplies the lacrimal apparatus is blocked first. The  supraorbital notch is palpated 
and the needle is inserted into the lateral edge of the medial third of the eyebrow and 
advanced to just medial to medial canthus and 2cc of the drug is injected. The tissue along the 
anterior lacrimal crest is infiltrated subcutaneously and the needle enters deeper at about 3 
mm medial to medial canthus, and without withdrawing the needle the drug is injected into 
deeper tissues up to periosteum both superiorly and inferiorly. A drop of topical proparacaine 
is placed in conjunctival cul de sac for intraoperative comfort. 
      The nose is packed with a ribbon gauze soaked with 0.5% Oxymetazolin  and 4% 
Lignocaine. The forceps should guide the ribbon gauze from the external nare superiorly and 
backwards so that it reaches the middle meatus, the site of ostium. 
 
Incision (colour plate pic 2) 
    After cleaning and draping, A straight 15 mm skin incision is made 10-12 mm nasal to the 
medial canthus and tangential to the inferonasal rim of orbit.  
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Sac Dissection 
       The orbicularis muscle is bluntly dissected, avoiding the angular vessels and the anterior 
limb of medial canthal tendon and periosteum are exposed. The skin and the orbicularis 
muscle are retracted medially and laterally with 4 stay sutures.. The anterior limb of the 
medial canthal tendon is incised exposing the lacrimal sac. The periosteum is incised and 
reflected posteriorly with theTraquair’s periosteal elevator. Anterior lacrimal crest and 
lacrimal fossa are exposed upto the posterior lacrimal crest. 
 
Bony ostium creation (colour plate pic 3) 
      After the exposure of the lacrimal fossa, the Traquair’s periosteal elevator is used to 
pierce the bone at the junction of lamina papyracea of the ethmoid and lacrimal bone or at the 
suture between the frontal process of maxilla and the lacrimal bone.Care is taken at this step 
not to damage the nasal mucosa. The Kerrison bone punch is gently inserted between the 
bone and the nasal mucosa and the ostium sequentially enlarged to around 12-15 mm size in 
both vertical and antero-posterior dimensions. 
 
The extent of the ostium can be up to 
a. Anteriorly till the punch cannot be inserted between the bone and the nasal mucosa. 
b. Posteriorly till removal of aerated ethmoid. 
c. Superiorly till 2 mm above the medial canthus. 
d. Inferiorly till the nasolacrimal canal is partly de-roofed. 
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Test Solution (colour plate pic 5 ) 
       The test solution was normal saline as placebo or 0.4mg/ml MMC as the interventional 
agent. This was soaked in a cottonoid and kept at the ostium site for 5 minutes.The ostium 
was thoroughly irrigated with 20 ml of normal saline.5 ml normal saline was used to irrigate 
the cornea and conjuctival sac. 
 
Flap formation 
       We followed the single anterior flap technique. 
        The first step is to create sac flap. A Bowman's probe is passed through the lower 
punctum and bent in such a way to tent the sac as posterior as possible to create a large 
anterior flap. Using the probe as guide, incision is made with the help of a number 11 Blade 
right across the sac from the fundus to the nasolacrimal duct. The incision is extended 
anteriorly from the two edges and the flap is raised. 
        The second step is to fashion the nasal mucosal flap. With the help of number 11 blade, 
incisions are made in the nasal mucosa along the bony ostium except anteriorly to have a 
hinged flap.  
 
Flap Anastomosis 
       The Nasal and Sac flaps are sutured edge to edge with 5-0 catgut.1 or more interrupted 
sutures are used depending on the size of the flaps. 
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Wound Closure 
      The orbicularis muscle is sutured with the same 5-0 catgut interrupted sutures. Skin is 
closed with interrupted 5-0 silk. Antibiotic ointment is applied to the wound and a sterile 
dressing is kept. 
 
Immediate Post Operative Care 
          On the 1
st
 post-operative day,the nasal pack and wound dressing is removed.The 
wound is cleaned with Betadine and left open.Patient is discharged on topical antibiotics and 
steroid drops for 1 week and analgesics .Oral antibiotics are not administered routinely unless 
there are signs of active infection. 
 
Outcome measures 
Subjective assessment of watering symptom –Munk Scoring of epiphora 
Functional assessment of lacrimal system-Fluorescein Dye Disappearance Test 
Anatomical patency –Syringing with Normal saline 
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Definition of Success 
 Subjective success was defined as substantial improvement to no watering or 
occasional watering requiring dabbing less than twice a day ie Munk Grade 0 and 1. 
 Objective success was taken as Fluorescein dye disappearance test Grade of 0 or +1 
indicating adequate tear drainage. 
 Anatomical patency was taken as fully or partially free flow on syringing of the ducts. 
Overall success was defined as fully or partially patent lacrimal system with subjective 
improvement in tearing and objective improvement in tear drainage. 
 
Follow up 
Patient was followed up at  
 1 week +/- 4 days 
 1month +/- 1 week 
 3 months +/- 2 weeks 
Sutures were removed at the 1
st
 visit 
Munk scoring,FDDT grading and Syringing were done at each visit. 
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Method of Randomisation 
Computer generated block randomization with variable block sizes of 4, 6 and 8. 
 
Blinding 
      Patient, Principal Investigator (PI),Surgeon and the Outcome Assessor were masked in 
the study. 
       The patient is unaware of which study group he/she belongs until the final follow up is 
over. Serially numbered sealed opaque envelopes were kept in safe custody of  the theatre in-
charge nurse. When a DCR was told to be included in the study, he would open the envelope 
and prepare the appropriate solution to be used. The solution is then handed over to the scrub 
nurse without revealing the study arm .The surgeon also is masked as to what solution is 
being given. The post operative follow up evaluations were done by the Outcome Assessor, 
who was the PI in this case, being still masked. The theatre in-charge nurse keeps a file of all 
the patients and solution used which will be revealed to the PI only after 3 months follow up 
is completed for each patient. 
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Method of Allocation Concealment  
      Opaque sealed envelopes were used to conceal the sequence of random allocation. The 
envelopes were opened after recruitment of participant into the study. 
 
 
Institutional Review Board Approval 
     The study protocol was approved by the Institutional Review Board constituted as per the 
ICMR Guidelines. (Appendix A) 
 
Funding source 
    Our study was funded by the institution’s Fluid Research Grant. No funding was received 
from any external source. 
 
Clinical Trials Registry – India  
This study is registered with the Clinical Trials Registry India. It was registered on 06/02/2013. 
The trial number is CTRI/2013/02/003352. (Appendix E) 
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Sample size Calculation 
        It would require 435 subjects in each study arm to show a statistically significant 
improvement in the success rate of external DCR from 90% to 95% with the application of 
MMC.Given the time constraints of a dissertation, this trial was initiated as a pilot study with 
a sample size of 90, ie 41 in each arm + 8 (10% attrition rate).We plan to continue this study 
in our department over the coming years. 
Two Proportion - Hypothesis Testing - Large Proportion - Equal Allocation 
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Liao 
 
Gonzalvo Gonzalvo 
1 sided α 
Gonzalvo 
with 90 
power 
Proportion in MMC group 0.97 0.97 0.95 1 1 1 1 1 
Proportion in Control 
group 
0.86 0.86 0.90 0.83 0.89 0.75 0.75 0.75 
Estimated risk difference  0.11 0.11 0.05 0.17 0.11 0.25 0.25 0.25 
Power (1- beta) % 80 80 80 80 80 80 80 90 
Alpha error (%) 5 5 5 5 5 5 5 5 
1 or 2 sided  2 1 2 2 2 2 1 2 
Required sample size for 
each arm  
100 78 435 41 66 26 21 35 
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Hypothesis testing of two large proportions Formula-Equal Allocation 
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Statistical Analysis 
 
        The collected data was entered into Microsoft Excel Spreadsheet and was analysed with 
the aid of SPSS Data Analysis Software version 16. 
        Mean ±SD was reported for continuous variables such as Age and Ostium, Frequency 
and % were reported as a descriptive statistics for all categorical variables. To compare the 
mean between respective groups for Age and Ostium, the Two Independent sample t test was 
used. All categorical variables were analyzed using Chi-square/Fishers exact test. 
        Overall success rate was compared with two-propotion Z test. P value <0.05 was 
considered to be statistically significant. 
 
 
 
 
 
 
. 
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RESULTS AND ANALYSIS 
Flow Chart of study patients  
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
Total No of Primary Adult 
NLDB Screened =76 
 
Not met inclusion criteria-10 
Planned DCT=1 
Planned DCR with Intubation=2 
Outstation patients=3 
Patient not willing to 
participate=2 
Consent not obtained=2 
 
   Total No Randomised=66 
 
  Protocol violation =6 
(excluded from analysis) 
Test solution used for incorrect 
duration  -3 
Converted to DCT-1 
Test solution not used-2 
 
    Final No Analysed N = 60 
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                                                                     1 week follow up   
                                                 
                                                             1month follow up 
  
                                                              3 month follow up 
 
 
 
 
 
 
 
Control group 
n=30 
 
MMC group 
n=30 
 
30 patients(100%) reported 
 
30 patients(100%) reported 
 
25 patients(83%) reported 
 
27 patients(90%) reported 
 
26  patients (87%) reported 
 
27 patients (90%) reported 
 
        No of lost to Follow up   
       4 (13%) 
 
No of lost to Follow up 
  3(10%) 
 
    Final No Analysed N = 60 
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Analysis 
1.Age 
        The age of patients included in the study ranged from 22 years to 85 with a mean age of  
 50.4 ± 15.6 years in the MMC group and 51.4 ± 13.7 years in the Control group.  
        Most of the patients i.e. 38/60 (63.3%) came under the middle aged category of 40-70 
years (Table 2 ,Fig 1). 
         
 Table 2:   Age Group distribution among study groups 
Age Group 
(years) 
MMC 
n (%) 
Control 
n (%) 
 
 
    P value 
 
    
 
 
 
 
 
        0.776 
18-30 4 (13.3) 3 (10.0) 
31-40 6 (20.0) 4(13.3) 
41-50 4 (13.3) 7 (23.3) 
51-60 8 (26.7) 7 (23.3) 
61-70 5 (16.7) 7 (23.3) 
71-80 3 (10.0) 1 (3.3) 
>80 0 (0.0) 1(3.3) 
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Fig.1 - Age Group distribution among study groups 
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2.Gender distribution: 
      47 out of 60 patients (78.3%) were females and 13 out of 60 (21.7%) were males. They 
were equally distributed in both arms. Thus there was a female prepoderence in our study. 
(Table 3, Figure 2) 
Table 3: Gender distribution among patients 
Gender MMC 
n (%) 
Control 
n (%) 
 p value 
     
Male 7 (23.3) 6( 20)           0.754 
Female 23 (76.6) 24 (80)   
 
 
 
Fig 2: Gender distribution among patients 
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3.Occupation:  
     57 out of 60 patients (95%) were doing either house jobs or manual labour. 
(Table 4, Figure 3) 
Table 4: Occupation of patients in each group 
Job MMC 
n (%) 
Control 
n(%) 
 
 
P value 
 
House Job 21(70) 19 (63.3)  
 
 
0.779 
Manual labour 7 (23.3) 10 (33.3) 
Business 1 (3.3) 1 (3.3) 
Others 1 (3.3) - 
 
 
Fig 3: Occupation of patients in each group 
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4.Socio Economic Status (SES) 
      53 out of 60 (88.3%) patients belonged to Low socio economic class and the rest 
belonged to the middle class. (Table 5, Figure 4) 
Table 5: Socio Economic Status of study patients 
SES MMC 
n (%) 
Control 
 n(%) 
        P value 
 
Low 26 (86.7) 27(90)  
        1.000 
Middle 4 (13.3) 3 (10) 
High - - 
 
 
  Fig 4: Socio Economic Status of study patients 
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5. Demography 
     78.3% of patients were from Vellore district while the rest were from neighbouring 
districts of Tamil Nadu,Andhra Pradesh and Karnataka.(Table 6, Figure 5) 
Table 6: Demographic distribution of patients 
Place MMC 
 n (%) 
Control  
n (%) 
      P value 
Vellore 23(76.7) 24 (80)           
           0.754 Neighbouring Districts 7 (23.3) 6 (20) 
    
 
 
 
Fig 5: Demographic distribution of patients 
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6.Co-Morbidities 
       The prevalence of Diabetes Mellitus among participants was 13.3% and Hypertension 
was 11.7%. None had any other systemic illnesses. (Table 7, Figure 6 &7) 
 
 
Table 7: Prevalence of Diabetes and Hypertension among patient groups 
Co-morbidity MMC  
n (%) 
Control  
n (%) 
 P value 
     
Diabetes mellitus 5 (16.7) 3(10)  0.706 
Hypertension 6 (20) 1 (3.3)  0.103 
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Fig 6 :Prevalence of Diabetes among patient groups 
 
 
Fig 7: Prevalence of Hypertension among patient groups 
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7.Anterior Rhinoscopy 
       Pre-operative Anterior Rhinoscopy by Thudicam speculum did not reveal any nasal 
pathology significant enough to be addressed before a DCR surgery.In one patient with 
Deviated Nasal Septum and spur,the spur was small and did not touch the lateral wall of nose. 
(Table 8) 
 
Table 8: Results of Pre op Anterior rhinoscopy 
Anterior Rhinoscopy MMC 
 n (%) 
Control 
 n (%) 
      P value 
    
 
         
         1.000 
Normal 15(50) 15 (50) 
DNS 15 (50) 15 (50) 
DNS with Spur 1 (3.3) 0 (0) 
Atrophic Rhinitis 0 (0) 0 (0) 
Nasal polyp 0 (0) 0 (0) 
 
 
 
 
 
 
61 
 
 
 
 
8. Pre-operative Munk score 
    Most patients in both arms 93.3% in MMC group and 90% in Control group had constant 
tearing (Grade 5) according to the Munk Grading System.(Table 9) 
 
 
Table 9: Pre operative Munk score among groups 
Munk score MMC 
 n (%) 
Control 
 n (%) 
 
 
     P value 
 
    
 
 
 
 
 
      1.000 
Grade 1 - - 
Grade 2 - 1(3.3) 
Grade 3 1(3.3) 1(3.3) 
Grade 4 1(3.3) 1(3.3) 
Grade 5 28(93.3) 27(90) 
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9. Pre-operative Fluorescein Dye Disappearance test (FDDT) 
All patients (100%) in MMC group and Control group had inadequate dye clearance after 5 
minutes (+2 or more).   (Table 10) 
 
Table 10: Pre-operative Fluorescein Dye Disappearance test score among patient groups 
FDDT Grade MMC 
n (%) 
Control  
n (%) 
   P value 
    
 
 
 
 
 
 
   1.000 
0 - - 
+1 - - 
+2 - 1(3.3) 
+3 2(6.7) 1(3.3) 
+4 28(93.3) 28(93.3) 
 
 
10. Pre-Operative Ducts Syringing 
      All patients in both arms had fully blocked nasolacrimal ducts with a hard touch and fluid 
regurgitating through the opposite punctum. 
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11. Surgeon Factor 
     Only 4 out of 60 DCRs (6.7%) was done by Consultants while the rest were done by 
Registrars. (Table 11) 
Table 11: Surgeon distribution among patient groups 
Surgeon MMC  
n(%) 
Control 
n (%) 
     P value 
    
 
 
0.612 
Consultant 3(10) 1(3.3) 
Registrars 27(90) 29(96.7) 
 
 
 
12.Intra-operative Ostium Size 
The intra-operative ostium size varied from 81 mm
2 
to 225 mm
2
 in our study patients. 
The mean ostium size in MMC group was 155.0 ± 24.7 mm
2 
 The mean ostium size in Control group was 149.8 ± 27.1 mm
2 
There was no significant difference in the ostium sizes between the 2 groups 
 (Table 12, Figure 8) 
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Table 12: Intraoperative ostium size distribution among patient groups 
Ostium Size mm
2 
MMC 
n(%) 
Control 
n(%) 
 P value 
    
 
 
0.441 
<120 2 (6.7) 5 (16.7) 
>121 28 (93.3) 25 (83.3) 
 
 
 
Fig 8:  Intraoperative ostium size distribution among patient groups 
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13. Per-operative Complications 
      2 patients in the MMC group had an incomplete nasal mucosal flap.There was no 
excessive bleeding noted in this group. 
      One patient in the Control group had an incomplete nasal mucosal flap and one patient 
had excessive per-operative bleeding and an incomplete nasal flap.The bleeding was 
controlled with ligation of the angular vein and pressure packing.No other per operative 
complication occurred during our study. (Table 13) 
 
 
Table 13: Distribution of Intra-operative complication among patient group 
Complication MMC 
n (%) 
Control 
n (%) 
      P value 
    
 
 
      1.000 
Nil 28 (93.3) 28(93.3) 
Excess Bleeding - 1 
Incomplete flap 2(6.7) 2(6.7)* 
 
*Same patient had excessive bleeding and incomplete flap. 
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14.Follow up 
 
There was 100% follow up compliance for the 1
st
 follow up visit at 1 week. 
There was 86.7% compliance at 1 month follow up. 
There was 88.3% compliance at 3 months follow up. (Table 14) 
 
Table 14:Follow up compliance among patient groups 
Visit MMC 
n(%) 
Control 
n(%) 
   
1 week 30 (100) 30 (100) 
1 month 25 (83.3) 27 (90) 
3 month 26 (86.7) 27 (90) 
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15. Time of Suture Removal  
 
       Suture remvol was generally done within 10th post operative day. In 3 cases of MMC 
group and 2 cases of Control group,it was done within the 14
th
 post operative day.In all the 5 
cases in which sutures were removed beyond 10 days, there was no evidence of wound 
necrosis and the delay in suture removal was the surgeon’s choice because of  reasons 
unrelated to wound health.(Table 15) 
 
 
 
Table 15: Timing of suture removal 
Time of suture 
removal 
MMC 
n (%) 
Control 
n (%) 
       P value 
 
    
 
        1.000 
5-10 days 27 (90) 28 (93.3) 
10-14 days 3 (10) 2 (6.7) 
>14 days - - 
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16. Result Analysis at 1
st
 week Post DCR 
Table 16: Post operative outcomes at 1week follow up 
Test MMC 
n=30(%) 
Control 
n=30(%) 
P value 
 
    
 
 
 
0.854 
 
 
 
 
Munk Score   
                     0 22 (73.3) 21 (70) 
                     1 1   (3.3) 2 (6.7) 
                     2 4  (13.3) 3 (10) 
                     3 2 (6.7) 4 (13.3) 
                     4 1 (3.3) - 
    
 
 
 
 
1.000 
 
 
 
 
FDDT   
                     0 - - 
                    +1 21 (70) 21 (70) 
                    +2 6 (20) 5 (16.7) 
                    +3 2 (6.7) 3 (10) 
                    +4 1 (3.3) 1 (3.3) 
    
 
 
0.353 
Ducts   
               Patent 29 (96.7) 26 (86.7) 
          Partially patent 1 (3.3) 3 (10) 
               Blocked - 1 (3.3) 
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       76.7 % patients in both the MMC group and the Control group had a Munk score of 0 or 
1 which was our definition of  subjective success 
     All patients in both groups had an improvement in tearing by at least 1 grade. 
     70% patients in both groups had adequate dye disappearance at 5 minutes. All other 
patients showed an improved dye disappearance except 1 patient each in both groups. 
      Syringing showed anatomical patency in all patients in MMC group and 96.7% in Control 
group  
      There was no statistically significant difference in success rate between the two groups at 
1 week follow up. (Table 17) 
 
Table 17: 1 week Success rate among both groups 
Variable MMC 
n=30 (%) 
Control 
n=30(%) 
P value 
Subjective success 23 (76.7%) 23 (76.7%) 1.000 
Functional success 21 (70%) 21 (70%) 1.000 
Anatomical success 30 (100%) 29 (96.7%) 0.287 
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17.  Result Analysis at 1 month Post DCR 
Table 18: Post operative outcomes at 1 month follow up 
Test MMC 
n=25 (%) 
Control 
n=27(%) 
P value 
    
 
 
0.566 
 
 
 
Munk Score   
0 18 (72.0) 24 (88.9) 
1 1 (4) - 
2 4 (16.0) 2 (7.4) 
3 1 (4.0) 1 (3.3) 
4 1 (4.0) - 
    
 
 
 
0.554 
 
 
FDDT   
0 - - 
+1 18 (72) 23 (85.2) 
+2 3 (12) 3 (11.1) 
+3 3 (12) 1 (3.7) 
+4 1 (4) - 
    
 
 
0.497 
Ducts   
Patent 21 (84) 25 (92.6) 
Partially patent 3 (12) 2 ( 7.4) 
Blocked 1 (4) - 
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      Subjective success was 76% in MMC group and 88.9% in control group. 
     All patients in both groups had a subjective improvement in watering by at least 1 grade. 
      72% patients in MMC group and 85.2% patients in Control group had adequate dye 
disappearance at 5 minutes. All patients had an improvement in dye disappearance by at least 
1 grade except for 1 patient in MMC group. 
       Syringing showed anatomical patency in 96% in MMC group and 100% in Control 
group.          
       There was no statistically significant difference in success rate between the Control and 
MMC group at 1 month. (Table 19) 
 
Table 19:1 month Success rate 
Variable MMC 
n=25 (%) 
Control 
n=27(%) 
P value 
    
Subjective success 19 (76) 224 (88.9) 0.258 
Functional success 18 (72) 23(85.2) 0.252 
Anatomical success 24(96) 27(100) 0.484 
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18. Result Analysis at 3 month Post DCR  
Table 20: Post operative outcomes at 3 month follow up 
Test MMC 
n=26 (%) 
Control 
n=27(%) 
P value 
 
    
 
 
 
 
0.457 
 
 
 
Munk Score   
                     0 21 (80.80) 24 (88.9) 
                     1 2 (7.7) 0 (0) 
                     2 3 (11.5) 2 (7.4) 
                     3 - - 
                     4 - 1 (3.7) 
FDDT    
 
 
 
0.544 
 
                     0 - - 
                    +1 21 (80.8) 23 (85.2) 
                    +2 3 (11.5) 3 (11.1) 
                    +3 2 (7.7) - 
                    +4 - 1(3.7) 
    
 
 
 
1.000 
Ducts   
               Patent 23 (88.5) 24 (88.9) 
           Partially patent 3 (11.5) 2  (7.4) 
               Blocked - 1 (3.7) 
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      Subjective success at 3 months was 88.5% in MMC group and 88.9% in Control group. 
All patients, except 1 patient in control group had an improvement in the tearing score by at 
least 1 grade.  
     80.8% in MMC group and 85.2% in Control group had adequate dye disappearance at 5 
minutes..All patients except 1 in Control  group had an improvement in dye disappearance by 
at least 1 grade. 
     Syringing showed anatomical patency in 100% patients in MMC group and 96.3% in 
Control group.  
     Thus at 3 month follow up, there was still no statistically significant difference in 
subjective and objective success rate in both groups. (Table 21) 
 
Table 21: 3 month Success Rate 
Variable MMC 
n=26 (%) 
Control 
n=27(%) 
 P value 
Subjective success 23 (88.5) 24 (88.9)  0.964 
Functional success 21(80.8) 23(85.2)  0.678 
Anatomical success 26(100) 26(96.3)  0.321 
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19.Post operative complications 
     There was 1 case in the Control group who had a post operative wound infection which 
was managed successfully with antibiotics and dressings and it healed well with a Munk 
score improvement to 2, FDDT score improvement to 2 and partially patent duct on syringing 
at 3 month follow up. 
 
20.Overall Success Rate 
A total of 3 patients had fully blocked ducts on syringing,with inadequate dye disappearance. 
There was also no patient satisfaction with regard to watering.One patient belonged to MMC 
group and 2 were in the Control group. (Table 22) 
Out of them only 2 patients came for 1 month follow up and only 1 patient came for the final 
visit. 
All 3 patients were advised revision DCR surgery. 
The overall success rate in the study was 96.7% (29/30) in the MMC group and 93.3 % 
(28/30) in the Control group and the difference was not statistically significant (p=0.546). 
(Table 23, Fig 9) 
. 
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Table 22: Analysis of failure cases 
Parameter Patient 1 Patient 2 Patient 3 
Arm Control MMC Control 
Age(Years) 61 42 61 
Co-Morbidities Nil Nil Nil 
Surgeon Registrar Registrar Registrar 
Intra Op Ostium 
size (mm
2
) 
120 81 110 
Intra-operative 
complication 
Nil Nil Nil 
Post-operative 
complication 
Nil Nil Nil 
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Table 23: Overall Success Rate  
MMC group 
 n=30 (%) 
Control group 
n=30 (%) 
           P value  
     
                
          0.546  ( 95% CI) 29/30 (96.7) 28/30 (93.3) 
 
 
 
 
Fig 9: Overall success rates in two groups 
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21. Correlation between Intra-operative Ostium size and Success at 3 months 
          Even though all 3 patients whose DCR failed belonged to the smaller ostium group, 
there was found to be no statistically significant association between the ostium size and final 
outcome. But in the control group,the probability of higher success with larger ostia was 
closer to statistical significance but not significant enough to draw conclusions.(Table 24) 
 
 
 
Table 24: Correlation between Intra-operative Ostium size and Success at 3 months 
Arm 
Ostium group(mm
2
) 
              MMC n =26 
<120                           >121 
            Control n= 27 
<120                                   >121 
Munk 0/1 
Pvalue 
1/1                                21/25 
                1.000 
2/3                                      22/24 
                  0.119                   
FDDT 0/+1 
P value 
1/1                               20/25 
                1.000 
1/3                                       22/24 
                   0.049 
Full/Partial Duct Patency 
P value 
1/1                               25/25 
                1.000 
2/3                                       24/24 
                   0.119 
 
 
 
78 
 
 
 
 
 
DISCUSSION 
             External DCR has remained the gold standard for the surgical management of 
nasolacrimal duct obstructions ever since the current  technique was introduced  by Toti in 
the early 20
th
 century(15).The introduction of flap suturing by  Depuy-Dutemps and Bourguet 
in the 1920s achieved a success rate of upto 94% (1).Since then lacrimal surgeons have been 
trying to  find out reasons for failure and improve on the results by various means. 
        With the advent of endoscopes, powerful lasers and drills in the 1980s, the endonasal 
approach has been gaining popularity and is getting closer to the success rates achieved by 
the conventional techniques. The success rates of Ext DCR has been reported to vary between 
65-100% and that for the Endo DCR 47-94% as shown in a review of literature(32).More 
importantly, endoscopic evaluations of the nasal ostium in failed cases have brought to light 
the major reasons of the failure. 
       Major reasons reported for failure in DCR are scarring within the anastomosis and at the 
common canaliculus,closure of the ostium by granulation tissue, adhesions to the medial wall 
of nose, and new bone formation. 
        Thus logically the idea of wound modulation with antifibrotic agents came up hoping to 
prevent excessive fibroblast proliferation and scarring and thus improve the outcome of 
surgery. Mitomycin C was first used in 1980s to improve success in trabeculectomy surgeries 
and now it has established itself as a safe adjuvant in many other surgeries in 
ophthalmology(55)(57)(60).It is  an alkylating agent used in cancer treatment and it inhibits 
DNA-dependent RNA synthesis thus reducing fibroblast collagen synthesis. 
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         The primary aim of our study was to find out the efficacy of MMC when used 
intraoperatively in primary adult nasolacrimal duct obstructions. 
       We studied 60 cases of PANDO which was randomised to a MMC group and a Control 
group of 30 each. 
       The age distribution of our patients were more in the middle age category ie 40-70 years  
with a mean age of  51.4 and 50.4 years respectively in MMC and control group. This 
distribution was seen in other studies as well. 
       Our study showed a female preponderance in the incidence of PANDO with 47/60 
(78.3%) patients being females. This distribution has been consistent in all previous 
studies(8)(9)(10)(11) proving the increased vulnerability of  women to duct obstruction. It 
has been suggested that the smaller diameter of the inferior bony lacrimal fossa and lacrimal 
canal in females could contribute to this observation. 
        88.3% patients belonged to the low socio-economic strata and most (95%) were daily 
wage workers doing hose jobs or manual labour. 
      31/60 (51.6%) patients had a deviated nasal septum which did not cause a negative 
impact on the outcome of surgery. However we had excluded cases with severe DNS 
touching the lateral wall and with other intranasal pathologies.  
      The overall success rate was 96.7% in the MMC group and 93.3% in the Control 
group and the difference was not statistically significant (p=0.546). This result was 
comparable with previous  studies which used MMC in Ext-DCR (Table 1).They had 
reported success rates between 90 -100% for the MMC group and between 73-92% for the 
control groups. Only 4 studies could prove a statistically significant difference while the 
majority of studies showed no statistical significant advantage in using MMC. 
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        The final subjective success rate at 3 months follow up was 88.5% in MMC group and 
88.9% in control group which was less than the anatomical patency of 100% in MMC group 
and 96.3 % in controls. Rose had described this as the “Lacrimal paradox” where  anatomical 
success may not correlate to success in control of symptoms and vice versa. There could be a 
hydraulic resistance to the flow of tears from the lateral canthus to the nasal cavity even with 
a patent passage. Previous studies have also shown similar results.(34)(35) 
        The average intraoperative ostium size in our study  was 155 mm
2
 and 149.8 mm
2  
respectively in MMC and control groups. There is a general suggestion that a larger 
osteotomy is needed for a large anastomosis and higher success rates. Some authors have 
even reported 100% success rates with a osteotomy size of 400mm
2
(38).Our study could not 
establish a correlation between the initial ostium size and final success though all 3 cases 
which failed had an initial narrower ostium(<120mm
2
). But an important observation by 
Linberg that the final healed ostium size shrinked to 1.8 mm after few months of surgery with 
excellent functional results to the patient, questions the need of very large osteotomies 
increasing the risk of CSF rhinorrhoea and haemorrhage.(20) 
         The dose and duration of exposure of Mitomycin C is not standardised for the use in 
DCR. Previous studies has used doses from 0.05 -1mg /ml with exposure time varying from 2 
minutes to 30 minutes (Table 1). Higher concentrations have shown to give better results as 
regards to final success and ostium size but the differences were not statistically significant. 
We used 0.4mg/ml for 5 minutes with good success outcomes. 
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            We did a single anterior flap anastomosis technique in this study.We found this to be 
technically easier and less time consuming. In the posterior part of the osteotomy site, the sac 
and nasal mucosa are in close proximity and are likely to scar together. The advantage of 
posterior flap suturing causing less of healing by granulation and higher success rates was 
matched in this study with the single flap technique. 
 
        There were no serious adverse effects of Mitomycin C noted in our study as has been 
with previous studies. 
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LIMITATIONS OF OUR STUDY 
 
       The major limitations of our study are the short follow up period of 3 months and limited 
number of participants. Most previous studies have followed the patients up from 6 months to 
35 months. It has been observed that the success rate of DCR decreases as time passes on.  
 
        The skill of the surgeon is a major confounding factor with has not been addressed in 
this study. Most of the cases has been done by registrars who are in various stages of 
learning. One previous study has shown statistically significant difference in success rates 
between cases done by trainees and consultants. Thus detailed attention to make a large, 
properly positioned and uniform rhinostomy, careful dissection to expose the true lumen of 
the lacrimal sac, atraumatic handling of the flaps and careful suturing of mucosal flaps, are 
important determinants of surgical success. 
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CONCLUSION 
 
 
      There was no statistically significant difference between the success rates of Primary 
External DCR with and without the use of intraoperative Mitomycin C in Primary Adult 
Nasolacrimal Duct Obstruction. 
 
       Mitomycin C application may not be beneficial in Primary External DCR for Primary 
Adult Nasolacrimal Duct Obstruction. 
 
       There was no complications related to the intraoperative use of 0.4mg/ml Mitomycin C 
for 5 minutes in Primary External DCR. 
 
       However, more randomized control trials involving more participants and longer follow 
up are required to establish the potential benefit of antimetabolites in Primary DCR surgery. 
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Appendix B-Patient information sheet 
Christian Medical College, Vellore 
Department of Ophthalmology 
 
Efficacy of  Mitomycin C in External Dacryocystorhinostomy-A Randomized control  trial 
 
Patient Information sheet 
 
You are being requested to participate in a study to see if a drug called Mitomycin C(MMC) 
when used in External Dacryocystorhinostomy(DCR) operation,can improve its success rate 
.We hope to include about 90 people from this hospital in this study. 
What does Mitomycin C(MMC) do when used in DCR? 
The major cause for longterm failure of DCR is the scarring and contraction of an opening 
made in the nose to facilitate tears drainage.MMC is a drug having anti-scarring properties 
and is widely used in other ophthalmic surgeries with high safety profile.Thus if tried in 
DCR,it could reduce the longterm contraction of the nose opening thus giving a higher 
success rate.But this has to be proved with studies so that it can be universally accepted.  
Does MMC have any side effects? 
MMC is a chemotherapeutic agent which inhibit DNA synthesis.It is used to treat intestinal 
and bladder cancers. Current applications in ophthalmology include pterygium surgery, 
glaucoma surgery, corneal refractive surgery, cicatricial eye disease and conjunctival  tumors 
.Local side effects include necrosis of nasal mucosa,excessive nasal 
bleeding,infection,inadvertent instillation into eye which can cause epithelial defects,sclera 
thinning,puntal occlusion and ulcer formation.But MMC is diluted and used in concentrations 
of 0.02-0.05% which causes the desired effect and minimal damage.Studies thus far have not 
shown any serious side effects in its use in DCR with one report of delayed skin wound 
healing and increased bleeding during surgery. 
 
If you take part what will you have to do? 
If you agree to participate in this study, you will be allotted into either of 2 groups.For those 
in Group 1,MMC will be used during DCR and for Group 2 MMC will not be used.Niether 
you or your doctor will have any choice or control over who goes to which group.That will be 
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randomly selected by the computer.Also you nor the doctor will be aware of who is in which 
group until the study is over.All other treatments that you are already on will be continued 
and your regular treatment will not be changed during this study. You will be expected to 
come for a review to the hospital  1 week  after surgery for suture removal and irrigation of 
the ducts and again after 1 month and finally after 3 months.Before starting the study and at 
each visit syringing of the ducts and also examination for any complications will be done. No 
additional procedures or blood tests will be conducted routinely for this study. 
If at any time you experience any problems, you will be expected to report this to the doctor. 
You will also be contacted by telephone at least once in between the monthly visits by the 
doctors in this study who will ask you about any problems  you are experiencing.  
Can you withdraw from this study after it starts? 
Your participation in this study is entirely voluntary and you are also free to decide to 
withdraw permission to participate in this study. If you do so, this will not affect your usual 
treatment at this hospital in any way. In addition, if you experience any serious side effects or 
your condition worsens, you may be given additional treatment.  
What will happen if you develop any study related injury? 
We do not expect any injury to happen to you but if you do develop any side effects or 
problems due to the study, these will be treated at no cost to you. We are unable to provide 
any monetary compensation, however.  
Will you have to pay for the surgery?  
The drug MMC will be supplied for you free of cost but you will have to bear the whole cost 
of the surgery and the hospital bill. 
Any other treatment that you usually take will continue but the usual arrangements that you 
have with the hospital will decide how much you pay for this.  
What happens after the study is over? 
You will be briefed about the results of the study and the benefits/side effects that you have 
had. 
Will your personal details be kept confidential? 
The results of this study will be published in a medical journal but you will not be identified 
by name in any publication or presentation of results. However, your medical notes may be 
reviewed by people associated with the study, without your additional permission, should you 
decide to participate in this study.  
 
If you have any further questions, please ask Dr.Vinod Joshua or  Dr.Jayanthi Peter 
(tel: 0416 3071201/ 3071205) or email: drvinodjoshua@gmail.com  
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                                      Appendix C-Informed Consent Form 
   
   
Efficacy of  Mitomycin C in External Dacryocystorhinostomy-A Randomized controlled trial 
Study Number: 
 
Participant’s name:  
Date of Birth / Age (in years): 
 
I_____________________________________________________________ 
___________, son/daughter of  ___________________________________ 
 
(Please tick boxes) 
Declare that I have read the information sheet provide to me regarding this study and have 
clarified any doubts that I had. [ ] 
I also understand that my participation in this study is entirely voluntary and that I am free to 
withdraw permission to continue to participate at any time without affecting my usual 
treatment or my legal rights [ ] 
I also understand that neither I, nor my doctors, will have any choice or knowledge of 
whether I will receive Mitomycin C during my operation [ ]  
I also understand that  the Mitomycin C will be provided free but I may have to pay for the 
rest of the expenses [ ] 
I understand that I will receive free treatment for any study related injury or adverse event but 
I will not receive any other financial compensation [ ] 
I understand that the study staff and institutional ethics committee members will not need my 
permission to look at my health records even if I withdraw from the trial. I agree to this 
access                                                                                                                                                                    
[ ] 
I understand that my identity will not be revealed in any information released to third parties 
or published [ ]   
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I voluntarily agree to take part in this study [ ] 
 
Name: 
Signature: 
Date: 
 
Name of witness: 
Relation to participant: 
Date: 
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                           Tamil Information Sheet and Consent Form 
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Hindi Information sheet and Consent form 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
107 
 
 
 
 
 
 
 
 
 
108 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
              
                 
 
109 
 
 
 
 
Telugu Information sheet and Consent Form 
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Appendix D-Clinical Research Form 
 
 
Study no  
Study Group  MMC               /                 Control 
Date of Enrollment  
Name  
Age  
Sex Male / Female 
Occupation  
Hospital No  
Address 
 
 
 
Socio Economic Status Low/ Middle / High 
Contact No  
Any co-morbidities- 
DM/HT/Keloid tendencies/Immunosupressive 
states/Bleeding tendencies/Others 
 
Anterior Rhinoscopy  
Pre op Epiphora Score  
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Pre op Fluorescein Dye Disappearance Test 
Normal / Inadequate; Score- 
Pre op-Syringing Blocked / Partially free 
Date of DCR  
Surgeon Registrar / Consultant 
IntraOp Ostium size (AP x Vertical mm
2
) ____mm  X   ____mm 
Duration of DCR in mins  
IntraOp complications 
 
 
 
Lost flap /Torn flap /Nil 
 
Bleeding –Severe /WNL 
Date of Suture removal  
1 week Post op -Date  
Epiphora Score  
Fluorescein Dye Disappearance Test Normal / Inadequate ; Score- 
Syringing Patent/Blocked 
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1 month Post op-Date  
Epiphora score  
Fluorescein Dye Disappearance Test Normal / Inadequate; Score- 
Syringing Patent/Blocked 
3 months Post op Date  
Epiphora score  
Fluorescein Dye Disappearance Test Normal / Inadequate;Score- 
Syringing Patent / Blocked 
 
Any Post Op Complications/Comments 
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Appendix E-CTRI Registration 
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Appendix F –Colour plates 
 
 
 
 
 
 
                     Picture 1: Septic OT  
 
 
 
 
 
 
 
          Picture 2: Skin incision 
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                          Picture 3: Creating the osteotomy with bone punch 
 
 
 
 
 
 
 
 
                        Picture 4:Blinded allocation of the test solution 
 
119 
 
 
 
 
 
 
 
 
 
 
 
 
              Picture 5: Placing the cottonoid soaked in test solution  
 
 
 
                                 
 
 
 
                  Picture 6: Measurement of Ostium size 
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Appendix G-Data sheet 
 
Legend 
Arm: MMC=1 Control= 0 
Age group:18-30 =1;31-40=2;41-50=3;51-60=4;61-70=5;71-80=6;>80=7 
Sex:Male=1;Female=0 
Occupation:House job=1;Manual labour=2;Bussiness=3;Retd=4 
Co-morbidity: Nil=0;DM=1;HTN=2;IHD=3;CVA=4;Others=5 
Anterior Rhinoscopy:Normal=0;DNS=1;DNS with spur=2;Allergic Rhinitis=3;Others= 4 
Surgeon:Consultant=1;Registrar =2 
Osteum group:<120 =0;>121=1 
OP complications:Nil=0;Excess bleed=1;Lost flap=2;Incomplete flap=3 
Suture removal:5-10 days=1;>10days =2 
Follow up:Completed =1;Lost=0 
Post Op complications:Nil=0;Delayed wound healing=1;Wound 
infection=2;Failure=3;Excessive nasal bleed=4;Others=5 
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